PLK4 Human shRNA Lentiviral Particle (Locus ID 10733)
CAT#: TL320644V
PLK4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
Need custom lentivirus service?
Get a free quote
CNY 11,400.00
Cited in 1 publication. |
Product images
CNY 2,950.00
CNY 1,999.00
CNY 2,700.00
Specifications
Product Data | |
Product Name | PLK4 Human shRNA Lentiviral Particle (Locus ID 10733) |
Locus ID | 10733 |
Synonyms | MCCRP2; SAK; STK18 |
Vector | pGFP-C-shLenti |
Format | Lentiviral particles |
RefSeq | NM_001190799, NM_001190801, NM_014264, NM_014264.1, NM_014264.2, NM_014264.3, NM_014264.4, NM_001190801.1, NM_001190799.1, BC036023, BC036023.1, NM_014264.5, NM_001190799.2 |
Summary | This gene encodes a member of the polo family of serine/threonine protein kinases. The protein localizes to centrioles, complex microtubule-based structures found in centrosomes, and regulates centriole duplication during the cell cycle. Three alternatively spliced transcript variants that encode different protein isoforms have been found for this gene. [provided by RefSeq, Jun 2010] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Polo‑like kinase 4 promotes tumorigenesis and induces resistance to radiotherapy in glioblastoma
,Wang, J;Zuo, J;Wang, M;Ma, X;Gao, K;Bai, X;Wang, N;Xie, W;Liu, H;,
Oncol. Rep.
,PubMed ID 30816483
[PLK4]
|
Documents
Product Manuals |
FAQs |
SDS |